5 research outputs found
Patient Profile.
<p>EGFR, epidermal growth factor receptor; m+, mutation-positive; PD, progressive disease; BSC, best supportive care.</p
Kaplan-Meier Plot.
<p>A, PFS of the patients who received second-line therapy; B, Survival time after termination of EGFR-TKI treatment among patients who received second-line chemotherapy. PFS, progression-free survival.</p
Patient characteristics.
<p>Abbreviations: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PD, progressive disease; BSC, best supportive care</p><p>Patient characteristics.</p
Additional file 1 of Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes
Additional file 1: Supplemental Figure 1. Lifestyle factors assessed in a dose-dependent manner using the least-squares method
Additional file 1: of A randomized phase II study to assess the effect of adjuvant immunotherapy using Îą-GalCer-pulsed dendritic cells in the patients with completely resected stage IIâIIIA non-small cell lung cancer: study protocol for a randomized controlled trial
SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOC 123Â kb